

Kwan Soo Byun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9111493/publications.pdf>

Version: 2024-02-01

53
papers

1,387
citations

393982

19
h-index

360668

35
g-index

53
all docs

53
docs citations

53
times ranked

2268
citing authors

#	ARTICLE	IF	CITATIONS
1	Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 427-437.e5.	2.4	33
2	Determinants of reâ€compensation in patients with hepatitis B virusâ€related decompensated cirrhosis starting antiviral therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 83-96.	1.9	13
3	MRE-based NASH score for diagnosis of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease. <i>Hepatology International</i> , 2022, 16, 316-324.	1.9	5
4	Primary prophylaxis of gastric variceal bleeding: endoscopic obturation, radiologic intervention, or observation?. <i>Hepatology International</i> , 2021, 15, 934-945.	1.9	11
5	Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. <i>Gut and Liver</i> , 2021, 15, 284-294.	1.4	33
6	Early Normalization of Alanine Aminotransferase during Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in HBV Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 1840.	1.0	11
7	Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2021, 15, 420-429.	1.4	11
8	Natural killer cell activity is a risk factor for the recurrence risk after curative treatment of hepatocellular carcinoma. <i>BMC Gastroenterology</i> , 2021, 21, 258.	0.8	14
9	Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 463-473.	4.5	2
10	Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2021, 11, 14639.	1.6	37
11	Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis. <i>Gut and Liver</i> , 2021, 15, 599-605.	1.4	18
12	<i>Lens culinaris</i> agglutinin-reactive fraction of alpha-fetoprotein improves diagnostic accuracy for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2021, 27, 4687-4696.	1.4	6
13	Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression. <i>PLoS ONE</i> , 2021, 16, e0255822.	1.1	5
14	Multiplexed Proteomic Approach for Identification of Serum Biomarkers in Hepatocellular Carcinoma Patients with Normal AFP. <i>Journal of Clinical Medicine</i> , 2020, 9, 323.	1.0	3
15	Multiparametric MR Is a Valuable Modality for Evaluating Disease Severity of Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00157.	1.3	16
16	Evaluation of Treatment Response after Endoscopic Variceal Obturation with Abdominal Computed Tomography. <i>Gut and Liver</i> , 2020, 14, 117-124.	1.4	5
17	Differential Impact of Serum 25-Hydroxyvitamin D3 Levels on the Prognosis of Patients with Liver Cirrhosis According to MELD and Child-Pugh Scores. <i>Journal of Korean Medical Science</i> , 2020, 35, e129.	1.1	4
18	Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1346-1353.	0.7	3

#	ARTICLE	IF	CITATIONS
19	Assessment and prediction of acute kidney injury in patients with decompensated cirrhosis with serum cystatin C and urine N-acetylglicosaminidase. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 234-240.	1.4	17
20	Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. <i>BMC Cancer</i> , 2019, 19, 363.	1.1	8
21	Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. <i>Journal of Hepatology</i> , 2019, 71, 35-44.	1.8	29
22	Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery. <i>Medicine (United States)</i> , 2019, 98, e17277.	0.4	16
23	How can we improve the performance of Model for End-Stage Liver Disease sodium score in patients with hepatitis B virus-related decompensated liver cirrhosis commencing antiviral treatment?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1641-1648.	1.4	7
24	Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 319-330.	4.5	88
25	CX3CR1 differentiates F4/80low monocytes into pro-inflammatory F4/80high macrophages in the liver. <i>Scientific Reports</i> , 2018, 8, 15076.	1.6	31
26	Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms. <i>Gut and Liver</i> , 2018, 12, 94-101.	1.4	14
27	The LAW index as an accurate indicator of the initiation of antiviral treatment in patients with chronic hepatitis B. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 208-214.	1.4	2
28	Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells. <i>Scientific Reports</i> , 2017, 7, 3710.	1.6	170
29	Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. <i>Hepatology</i> , 2017, 66, 772-783.	3.6	37
30	Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study. <i>Journal of Medical Virology</i> , 2017, 89, 849-856.	2.5	9
31	An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma. <i>Journal of Korean Medical Science</i> , 2017, 32, 212.	1.1	34
32	Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: A randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 331-339.	4.5	11
33	Complete response of advanced hepatocellular carcinoma to sorafenib : another case and a comprehensive review. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 340-346.	4.5	19
34	Changes in Cardiac Varices and Their Clinical Significance after Eradication of Esophageal Varices by Band Ligation. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2016, 2016, 1-9.	0.8	8
35	BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 467-474.	1.4	47
36	The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years?. <i>Liver International</i> , 2016, 36, 445-453.	1.9	22

#	ARTICLE	IF	CITATIONS
37	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 852-860.	6.1	70
38	Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 1042-1051.	6.1	76
39	Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 382-389.	4.5	19
40	Cyanoacrylate injection versus band ligation for bleeding from cardiac varices along the lesser curvature of the stomach. <i>Clinical and Molecular Hepatology</i> , 2016, 22, 487-494.	4.5	10
41	Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2015, 21, 12787.	1.4	51
42	Hepatoithiasis and intrahepatic cholangiocarcinoma: A review. <i>World Journal of Gastroenterology</i> , 2015, 21, 13418.	1.4	95
43	The Influence of Alcoholic Liver Disease on Serum PIVKA-II Levels in Patients without Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2015, 9, 224-230.	1.4	17
44	Clinical Characteristics and Outcomes of Acute Hepatitis A in Korea: A Nationwide Multicenter Study. <i>Journal of Korean Medical Science</i> , 2014, 29, 248.	1.1	18
45	Genomic Predictors for Recurrence Patterns of Hepatocellular Carcinoma: Model Derivation and Validation. <i>PLoS Medicine</i> , 2014, 11, e1001770.	3.9	117
46	Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s/t)ide Treatment Failure. <i>Gut and Liver</i> , 2014, 8, 64-69.	1.4	13
47	Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma. <i>Gut and Liver</i> , 2014, 8, 177-185.	1.4	40
48	Recurrence rates and factors for recurrence after radiofrequency ablation combined with transarterial chemoembolization for hepatocellular carcinoma: a retrospective cohort study. <i>Hepatology International</i> , 2012, 6, 505-510.	1.9	9
49	Factors Affecting Complete Small Bowel Study and Diagnostic Yield in MiroCam® Capsule Endoscopy. <i>Intestinal Research</i> , 2011, 9, 27.	1.0	0
50	Placement of a Covered Self-expandable Nitinol Stent for Bile Duct Stricture that was Caused by Ischemic Injury after Transcatheter Arterial Chemoembolization in a Patient with Hepatocellular Carcinoma: A Case Report. <i>Journal of the Korean Radiological Society</i> , 2008, 59, 241.	0.0	0
51	Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2005, 20, 1838-1842.	1.4	25
52	Detection of hepatitis A viral RNA in sera of patients with acute hepatitis A. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2000, 15, 1043-1047.	1.4	28
53	An Efficacy Evaluation of the Oral Administration Metadoxine in Korean Alcoholic Liver Patients: a Randomized, Placebo-Controlled Trial. <i>Journal of the Korean Society for Clinical Pharmacology and Therapeutics</i> , 1998, 6, 183.	0.1	0